Please provide your email address to receive an email when new articles are posted on . Resistant and refractory hypertension represent distinct disease states requiring different treatments. A ...

Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.

Findings showed baxdrostat at both doses significantly reduced mean systolic blood pressure compared with placebo at week 12. Topline data were announced from a phase 3 trial that evaluated baxdrostat ...

Findings showed treatment with lorundrostat resulted in statistically significant reductions in systolic blood pressure compared with placebo. Topline data were announced from a phase 3 trial ...

Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators. Aprocitentan, a dual endothelin receptor A and B ...

CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...

Resistant hypertension is a serious form of high blood pressure that persists despite the use of at least three antihypertensive medications from different classes, including a diuretic. In a recent ...

A new drug that significantly lowers "stubborn" blood pressure is on the horizon, following the results of its Phase III clinical trial. The treatment, called baxdrostat, has been hailed as the most ...